The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.

by Muhammad Rauzan, Charles T H Chuah, Tun Kiat Ko, S Tiong Ong
Published 2017-01-01